Skip to Main Content

Inspire Medical Systems, Inc. (NYSE: INSP) Securities Fraud Investigation

August 4, 2025, Inspire issued a press release announcing its second quarter financial results and updating its 2025 outlook. Among other items, Inspire reduced its full-year revenue outlook and diluted net income per share. Inspire attributed the reductions to slower-than-expected progress of the commercial launch of its next generation “Inspire V” neurostimulation system.

On this news, Inspire’s stock price fell $42.04 per share, or 32.35%, to close at $87.91 per share on August 5, 2025.

If you have any questions or would like to discuss this investigation, please contact Kessler Topaz Meltzer & Check, LLP:  Jonathan Naji, Esq. (484) 270-1453 or via e-mail at info@ktmc.com.  

Complete this form with your transactions in Inspire Medical Systems, Inc. securities between August 2, 2023 and August 4, 2025.

Click Here to Print PDF of this Form

SUBMIT YOUR INFORMATION
* Denotes required field
Purchase(s)
+ Additional Purchases
Sale(s)
+ Additional Sales
Date
# of Shares
Price per Share
Date
Principal Amount
Amount Paid
Series or CUSIP
Date
# of Contracts
Price per Contract
Exercise Price
Expiration Date
Did you purchase shares of Inspire Medical Systems, Inc. prior to the Class Period?
Are you a current or former employee of Inspire Medical Systems, Inc. ?
The submission of this form does not create an attorney-client relationship, nor an obligation on the part of Kessler Topaz or you to file a lead plaintiff motion in this matter. Any information you submit will be maintained as confidential. If Kessler Topaz, in its sole discretion, believes that you might be an appropriate lead plaintiff candidate, Kessler Topaz will contact you to discuss the matter and whether to establish an attorney client relationship. By signing this form you are authorizing us to contact you regarding this case and/or future cases.
I agree to the KTMC disclaimer
I would like to receive new case alerts by email
Submit Your Information